Golden Throat Holdings Group Co Ltd 2023 AR2
The report highlights Golden Throat Holdings Group Company Limited's performance for the fiscal year 2023. The Group's flagship product, Golden Throat Lozenges (OTC), was awarded the No. 1 spot among Chinese traditional medicines (throat) by the China Nonprescription Medicines Association. Financially, the Group recorded a revenue of approximately RMB 961.4 million and a net profit of RMB 250.2 million. On the sustainability front, the Group completed its relocation to a new R&D and production base powered by clean natural gas-fired boilers and continued its commitment to employee welfare by providing electric vehicles to over 700 employees to reduce commuting carbon emissions.
Company: Golden Throat Holdings Group Co Ltd
Sector: Consumer Staples
Country: China
Year: 2023
Type: AR2
Pages: 178
Golden Throat Holdings Group Co Ltd
Annual Report
The report highlights Golden Throat Holdings Group Company Limited's performance for the fiscal year 2023. The Group's flagship product, Golden Throat Lozenges (OTC), was awarded the No. 1 spot among Chinese traditional medicines (throat) by the China Nonprescription Medicines Association. Financially, the Group recorded a revenue of approximately RMB 961.4 million and a net profit of RMB 250.2 million. On the sustainability front, the Group completed its relocation to a new R&D and production base powered by clean natural gas-fired boilers and continued its commitment to employee welfare by providing electric vehicles to over 700 employees to reduce commuting carbon emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Workplace Fatalities
Employees